According to a KFF poll, 62% of adults taking GLP-1 drugs reported using them to manage a chronic condition such as diabetes or heart disease, while about four in 10 said they were prescribed GLP-1s primarily to lose weight
Given the substantial disease burden and adverse health outcomes associated with this comorbidity, interventions aimed at reducing this risk for depression in the Type 2 diabetes population are crucial, particularly among older adults who are disproportionately affected by both conditions. Guo noted that previous research suggested that GLP-1RAs a drug also used to treat obesity and kidney disease may alleviate depression symptoms due to its ability to cross the blood-brain barrier
alkanethiols or thiolated-polymer)
A clinical study involving 564 adults (BMI 30-40 kg/m2, without T2DM) found that compared with orlistat (3120 mg, weight loss of 4.1 kg), LIR (subcutaneous administration of 1.2 mg/d, 1.8 mg/d, 2.4 mg/d or 3 mg/d) had an average weight loss of 4.8-7.2 kg, the two-year extended experiment of which also showed similar results (88, 89)
.jpeg)
